Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases.

Patel S, Webster JD, Varfolomeev E, Kwon YC, Cheng JH, Zhang J, Dugger DL, Wickliffe KE, Maltzman A, Sujatha-Bhaskar S, Bir Kohli P, Ramaswamy S, Deshmukh G, Liederer BM, Fong R, Hamilton G, Lupardus P, Caplazi P, Lee WP, van Lookeren Campagne M, Johnson A, McKenzie BS, Junttila MR, Newton K, Vucic D.

Cell Death Differ. 2019 May 17. doi: 10.1038/s41418-019-0347-0. [Epub ahead of print]

PMID:
31101885
2.

Safety Assessment of Ubiquinol Acetate: Subchronic Toxicity and Genotoxicity Studies.

Deshmukh G, Venkataramaiah SB, Doreswamy CM, Umesh MC, Subbanna RB, Pradhan BK, Seekallu S, Sekar R, Prabhu K, Sadagopan S, Arumugam SN, Sharma S, Gavara G, Balaraman S, Sambasivam G, Chandrappa RK, Flynn S, Shivarudraiah P.

J Toxicol. 2019 Apr 1;2019:3680757. doi: 10.1155/2019/3680757. eCollection 2019.

3.

Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group.

Hamilton GL, Chen H, Deshmukh G, Eigenbrot C, Fong R, Johnson A, Kohli PB, Lupardus PJ, Liederer BM, Ramaswamy S, Wang H, Wang J, Xu Z, Zhu Y, Vucic D, Patel S.

Bioorg Med Chem Lett. 2019 Jun 15;29(12):1497-1501. doi: 10.1016/j.bmcl.2019.04.014. Epub 2019 Apr 11.

PMID:
31000154
4.

Control of matting temperature during pressing of Paneer and its effect on Paneer quality.

Arvind SA, Ravindra MR, Manjunatha M, Emerald FME, Deshmukh GP, Datir R.

J Food Sci Technol. 2019 Apr;56(4):1715-1722. doi: 10.1007/s13197-019-03598-9. Epub 2019 Feb 1.

PMID:
30996407
5.

Conversion of curved assemblies into two dimensional sheets.

Deshmukh G, Krishnamoorthy K.

Nanoscale. 2019 Mar 21;11(12):5732-5736. doi: 10.1039/c8nr09915d.

PMID:
30865738
6.

Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma.

Dengler HS, Wu X, Peng I, Rinderknecht CH, Kwon Y, Suto E, Kohli PB, Liimatta M, Barrett K, Lloyd J, Cain G, Briggs M, Addo S, Salmon G, Ubhayakar S, Deshmukh G, Shahidi-Latham SK, Quiason-Huynh CM, Jackman J, Liu J, Ray NC, Goodacre SC, Johnson A, McKenzie BS, Lee WP, Zak M, Kenny JR, Ghilardi N.

Sci Transl Med. 2018 Nov 21;10(468). pii: eaao2151. doi: 10.1126/scitranslmed.aao2151.

PMID:
30463918
7.

Copper Catalyzed C-H Activation.

Kantam ML, Gadipelly C, Deshmukh G, Reddy KR, Bhargava S.

Chem Rec. 2018 Oct 30. doi: 10.1002/tcr.201800107. [Epub ahead of print] Review.

PMID:
30375153
8.

Use of Subcutaneous and Intraperitoneal Administration Methods to Facilitate Cassette Dosing in Microdialysis Studies in Rats.

Durk MR, Deshmukh G, Valle N, Ding X, Liederer BM, Liu X.

Drug Metab Dispos. 2018 Jul;46(7):964-969. doi: 10.1124/dmd.118.080697. Epub 2018 Apr 26.

PMID:
29700231
9.

Author's reply.

Babu PR, S Pravin AJ, Deshmukh G, Dhoot D, Samant A, Kotak B.

Indian J Dermatol. 2017 Nov-Dec;62(6):667-669. doi: 10.4103/ijd.IJD_496_17. No abstract available.

10.

Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease.

Patel S, Meilandt WJ, Erickson RI, Chen J, Deshmukh G, Estrada AA, Fuji RN, Gibbons P, Gustafson A, Harris SF, Imperio J, Liu W, Liu X, Liu Y, Lyssikatos JP, Ma C, Yin J, Lewcock JW, Siu M.

J Med Chem. 2017 Oct 12;60(19):8083-8102. doi: 10.1021/acs.jmedchem.7b00843. Epub 2017 Sep 20.

PMID:
28929759
11.

Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis.

Babu PR, Pravin AJS, Deshmukh G, Dhoot D, Samant A, Kotak B.

Indian J Dermatol. 2017 Jul-Aug;62(4):395-399. doi: 10.4103/ijd.IJD_191_17.

12.

First Direct Isolation of Stable α-Form Crystals of Mirabegron, a Selective β3-Adrenoceptor Agonist.

Deshmukh GD, Bangal NM, Mali CA, Medhane JV, Mathad TV.

Acta Chim Slov. 2017 Jun;64(2):461-466.

PMID:
28621388
13.

Localization of optic disc and fovea in retinal images using intensity based line scanning analysis.

Kamble R, Kokare M, Deshmukh G, Hussin FA, Mériaudeau F.

Comput Biol Med. 2017 Aug 1;87:382-396. doi: 10.1016/j.compbiomed.2017.04.016. Epub 2017 Apr 27.

PMID:
28595892
14.

From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.

Liang J, Labadie S, Zhang B, Ortwine DF, Patel S, Vinogradova M, Kiefer JR, Mauer T, Gehling VS, Harmange JC, Cummings R, Lai T, Liao J, Zheng X, Liu Y, Gustafson A, Van der Porten E, Mao W, Liederer BM, Deshmukh G, An L, Ran Y, Classon M, Trojer P, Dragovich PS, Murray L.

Bioorg Med Chem Lett. 2017 Jul 1;27(13):2974-2981. doi: 10.1016/j.bmcl.2017.05.016. Epub 2017 May 5.

PMID:
28512031
15.

Anti-Mullerian Hormone: A Marker of Ovarian Reserve and its Association with Polycystic Ovarian Syndrome.

Verma AK, Rajbhar S, Mishra J, Gupta M, Sharma M, Deshmukh G, Ali W.

J Clin Diagn Res. 2016 Dec;10(12):QC10-QC12. doi: 10.7860/JCDR/2016/20370.8988. Epub 2016 Dec 1.

16.

GluN2A-Selective Pyridopyrimidinone Series of NMDAR Positive Allosteric Modulators with an Improved in Vivo Profile.

Villemure E, Volgraf M, Jiang Y, Wu G, Ly CQ, Yuen PW, Lu A, Luo X, Liu M, Zhang S, Lupardus PJ, Wallweber HJ, Liederer BM, Deshmukh G, Plise E, Tay S, Wang TM, Hanson JE, Hackos DH, Scearce-Levie K, Schwarz JB, Sellers BD.

ACS Med Chem Lett. 2016 Oct 31;8(1):84-89. doi: 10.1021/acsmedchemlett.6b00388. eCollection 2017 Jan 12.

17.

Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.

Labadie SS, Dragovich PS, Cummings RT, Deshmukh G, Gustafson A, Han N, Harmange JC, Kiefer JR, Li Y, Liang J, Liederer BM, Liu Y, Manieri W, Mao W, Murray L, Ortwine DF, Trojer P, VanderPorten E, Vinogradova M, Wen L.

Bioorg Med Chem Lett. 2016 Sep 15;26(18):4492-4496. doi: 10.1016/j.bmcl.2016.07.070. Epub 2016 Jul 29.

PMID:
27499454
18.

Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.

Liang J, Zhang B, Labadie S, Ortwine DF, Vinogradova M, Kiefer JR, Gehling VS, Harmange JC, Cummings R, Lai T, Liao J, Zheng X, Liu Y, Gustafson A, Van der Porten E, Mao W, Liederer BM, Deshmukh G, Classon M, Trojer P, Dragovich PS, Murray L.

Bioorg Med Chem Lett. 2016 Aug 15;26(16):4036-41. doi: 10.1016/j.bmcl.2016.06.078. Epub 2016 Jun 29.

PMID:
27406798
19.

Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design.

Volgraf M, Sellers BD, Jiang Y, Wu G, Ly CQ, Villemure E, Pastor RM, Yuen PW, Lu A, Luo X, Liu M, Zhang S, Sun L, Fu Y, Lupardus PJ, Wallweber HJ, Liederer BM, Deshmukh G, Plise E, Tay S, Reynen P, Herrington J, Gustafson A, Liu Y, Dirksen A, Dietz MG, Liu Y, Wang TM, Hanson JE, Hackos D, Scearce-Levie K, Schwarz JB.

J Med Chem. 2016 Mar 24;59(6):2760-79. doi: 10.1021/acs.jmedchem.5b02010. Epub 2016 Mar 8.

PMID:
26919761
20.

Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21.

Dunshee DR, Bainbridge TW, Kljavin NM, Zavala-Solorio J, Schroeder AC, Chan R, Corpuz R, Wong M, Zhou W, Deshmukh G, Ly J, Sutherlin DP, Ernst JA, Sonoda J.

J Biol Chem. 2016 Mar 11;291(11):5986-96. doi: 10.1074/jbc.M115.710582. Epub 2016 Jan 21.

21.

Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12).

Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y, Ma C, Scearce-Levie K, Ghosh AS, Shin YG, Solanoy H, Wang J, Wang B, Yin J, Siu M, Lewcock JW.

J Med Chem. 2015 Oct 22;58(20):8182-99. doi: 10.1021/acs.jmedchem.5b01072. Epub 2015 Oct 2.

PMID:
26431428
22.

Use of cassette dosing to enhance the throughput of rat brain microdialysis studies.

Deshmukh G, Sun K, Liederer BM, Ding X, Liu X.

Drug Metab Dispos. 2015 Jul;43(7):1123-8. doi: 10.1124/dmd.115.064204. Epub 2015 May 5.

PMID:
25943358
23.

Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models.

Patel S, Cohen F, Dean BJ, De La Torre K, Deshmukh G, Estrada AA, Ghosh AS, Gibbons P, Gustafson A, Huestis MP, Le Pichon CE, Lin H, Liu W, Liu X, Liu Y, Ly CQ, Lyssikatos JP, Ma C, Scearce-Levie K, Shin YG, Solanoy H, Stark KL, Wang J, Wang B, Zhao X, Lewcock JW, Siu M.

J Med Chem. 2015 Jan 8;58(1):401-18. doi: 10.1021/jm5013984. Epub 2014 Oct 23.

PMID:
25341110
24.

Synthesis and biological evaluation of novel N-aryl maleimide derivatives clubbed with α-hydroxyphosphonates.

Patil NS, Deshmukh GB, Patil SV, Bholay AD, Gaikwad ND.

Eur J Med Chem. 2014 Aug 18;83:490-7. doi: 10.1016/j.ejmech.2014.06.053. Epub 2014 Jun 26.

PMID:
24992076
25.

Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.

Liu X, Cheong J, Ding X, Deshmukh G.

Drug Metab Dispos. 2014 Apr;42(4):482-91. doi: 10.1124/dmd.113.055590. Epub 2014 Jan 7.

PMID:
24398459
26.

Experiences of orthopaedic cAMP in a mobile surgical unit (life line express) in central part of India.

Deshmukh G, Raza H.

Malays Orthop J. 2013 Nov;7(3):36-41. doi: 10.5704/MOJ.1311.009.

27.

Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.

Labadie S, Barrett K, Blair WS, Chang C, Deshmukh G, Eigenbrot C, Gibbons P, Johnson A, Kenny JR, Kohli PB, Liimatta M, Lupardus PJ, Shia S, Steffek M, Ubhayakar S, van Abbema A, Zak M.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):5923-30. doi: 10.1016/j.bmcl.2013.08.082. Epub 2013 Aug 27.

PMID:
24042009
28.

Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.

Zak M, Hurley CA, Ward SI, Bergeron P, Barrett K, Balazs M, Blair WS, Bull R, Chakravarty P, Chang C, Crackett P, Deshmukh G, DeVoss J, Dragovich PS, Eigenbrot C, Ellwood C, Gaines S, Ghilardi N, Gibbons P, Gradl S, Gribling P, Hamman C, Harstad E, Hewitt P, Johnson A, Johnson T, Kenny JR, Koehler MF, Bir Kohli P, Labadie S, Lee WP, Liao J, Liimatta M, Mendonca R, Narukulla R, Pulk R, Reeve A, Savage S, Shia S, Steffek M, Ubhayakar S, van Abbema A, Aliagas I, Avitabile-Woo B, Xiao Y, Yang J, Kulagowski JJ.

J Med Chem. 2013 Jun 13;56(11):4764-85. doi: 10.1021/jm4004895. Epub 2013 May 31.

PMID:
23659214
29.

Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1.

Hurley CA, Blair WS, Bull RJ, Chang C, Crackett PH, Deshmukh G, Dyke HJ, Fong R, Ghilardi N, Gibbons P, Hewitt PR, Johnson A, Johnson T, Kenny JR, Kohli PB, Kulagowski JJ, Liimatta M, Lupardus PJ, Maxey RJ, Mendonca R, Narukulla R, Pulk R, Ubhayakar S, van Abbema A, Ward SI, Waszkowycz B, Zak M.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3592-8. doi: 10.1016/j.bmcl.2013.04.018. Epub 2013 Apr 17.

PMID:
23642482
30.

Mechanistic pharmacokinetic-pharmacodynamic modeling of BACE1 inhibition in monkeys: development of a predictive model for amyloid precursor protein processing.

Liu X, Wong H, Scearce-Levie K, Watts RJ, Coraggio M, Shin YG, Peng K, Wildsmith KR, Atwal JK, Mango J, Schauer SP, Regal K, Hunt KW, Thomas AA, Siu M, Lyssikatos J, Deshmukh G, Hop CE.

Drug Metab Dispos. 2013 Jul;41(7):1319-28. doi: 10.1124/dmd.112.050864. Epub 2013 Apr 12.

PMID:
23584887
31.

Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR).

Estrada AA, Shore DG, Blackwood E, Chen YH, Deshmukh G, Ding X, Dipasquale AG, Epler JA, Friedman LS, Koehler MF, Liu L, Malek S, Nonomiya J, Ortwine DF, Pei Z, Sideris S, St-Jean F, Trinh L, Truong T, Lyssikatos JP.

J Med Chem. 2013 Apr 11;56(7):3090-101. doi: 10.1021/jm400194n. Epub 2013 Mar 29.

PMID:
23473235
32.

Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.

Pei Z, Blackwood E, Liu L, Malek S, Belvin M, Koehler MF, Ortwine DF, Chen H, Cohen F, Kenny JR, Bergeron P, Lau K, Ly C, Zhao X, Estrada AA, Truong T, Epler JA, Nonomiya J, Trinh L, Sideris S, Lesnick J, Bao L, Vijapurkar U, Mukadam S, Tay S, Deshmukh G, Chen YH, Ding X, Friedman LS, Lyssikatos JP.

ACS Med Chem Lett. 2012 Nov 29;4(1):103-7. doi: 10.1021/ml3003132. eCollection 2013 Jan 10.

33.

High-throughput liquid chromatography/mass spectrometry method for the quantitation of small molecules using accurate mass technologies in supporting discovery drug screening.

Ding X, Ghobarah H, Zhang X, Jaochico A, Liu X, Deshmukh G, Liederer BM, Hop CE, Dean B.

Rapid Commun Mass Spectrom. 2013 Feb 15;27(3):401-8. doi: 10.1002/rcm.6461.

PMID:
23280971
34.

Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.

Koehler MF, Bergeron P, Blackwood E, Bowman KK, Chen YH, Deshmukh G, Ding X, Epler J, Lau K, Lee L, Liu L, Ly C, Malek S, Nonomiya J, Oeh J, Ortwine DF, Sampath D, Sideris S, Trinh L, Truong T, Wu J, Pei Z, Lyssikatos JP.

J Med Chem. 2012 Dec 27;55(24):10958-71. doi: 10.1021/jm301389h. Epub 2012 Dec 12.

PMID:
23199076
35.

Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.

Labadie S, Dragovich PS, Barrett K, Blair WS, Bergeron P, Chang C, Deshmukh G, Eigenbrot C, Ghilardi N, Gibbons P, Hurley CA, Johnson A, Kenny JR, Kohli PB, Kulagowski JJ, Liimatta M, Lupardus PJ, Mendonca R, Murray JM, Pulk R, Shia S, Steffek M, Ubhayakar S, Ultsch M, van Abbema A, Ward S, Zak M.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7627-33. doi: 10.1016/j.bmcl.2012.10.008. Epub 2012 Oct 11.

PMID:
23107482
36.

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.

Zak M, Mendonca R, Balazs M, Barrett K, Bergeron P, Blair WS, Chang C, Deshmukh G, Devoss J, Dragovich PS, Eigenbrot C, Ghilardi N, Gibbons P, Gradl S, Hamman C, Hanan EJ, Harstad E, Hewitt PR, Hurley CA, Jin T, Johnson A, Johnson T, Kenny JR, Koehler MF, Bir Kohli P, Kulagowski JJ, Labadie S, Liao J, Liimatta M, Lin Z, Lupardus PJ, Maxey RJ, Murray JM, Pulk R, Rodriguez M, Savage S, Shia S, Steffek M, Ubhayakar S, Ultsch M, van Abbema A, Ward SI, Xiao L, Xiao Y.

J Med Chem. 2012 Jul 12;55(13):6176-93. doi: 10.1021/jm300628c. Epub 2012 Jun 28.

PMID:
22698084
37.

Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.

Kulagowski JJ, Blair W, Bull RJ, Chang C, Deshmukh G, Dyke HJ, Eigenbrot C, Ghilardi N, Gibbons P, Harrison TK, Hewitt PR, Liimatta M, Hurley CA, Johnson A, Johnson T, Kenny JR, Bir Kohli P, Maxey RJ, Mendonca R, Mortara K, Murray J, Narukulla R, Shia S, Steffek M, Ubhayakar S, Ultsch M, van Abbema A, Ward SI, Waszkowycz B, Zak M.

J Med Chem. 2012 Jun 28;55(12):5901-21. doi: 10.1021/jm300438j. Epub 2012 Jun 11.

PMID:
22591402
38.

In vitro skin corrosion: Human skin model test - A validation study.

Deshmukh GR, Kumar KH, Reddy PV, Rao BS.

Toxicol In Vitro. 2012 Sep;26(6):1072-4. doi: 10.1016/j.tiv.2012.04.021. Epub 2012 Apr 27.

PMID:
22542585
39.

Use of the cassette-dosing approach to assess brain penetration in drug discovery.

Liu X, Ding X, Deshmukh G, Liederer BM, Hop CE.

Drug Metab Dispos. 2012 May;40(5):963-9. doi: 10.1124/dmd.111.044420. Epub 2012 Feb 10.

PMID:
22328585
40.

Evaluation of bivalves as bioindicators of metal pollution in freshwater.

Waykar B, Deshmukh G.

Bull Environ Contam Toxicol. 2012 Jan;88(1):48-53. doi: 10.1007/s00128-011-0447-0. Epub 2011 Nov 2.

PMID:
22045126
41.

Six sigma: process of understanding the control and capability of ranitidine hydrochloride tablet.

Chabukswar A, Jagdale S, Kuchekar B, Joshi V, Deshmukh G, Kothawade H, Kuckekar A, Lokhande P.

J Young Pharm. 2011 Jan;3(1):15-25. doi: 10.4103/0975-1483.76415.

42.

Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors.

Liu H, Kuhn C, Feru F, Jacques SL, Deshmukh GD, Ye P, Rennie GR, Johnson T, Kazmirski S, Low S, Coli R, Ding YH, Cheng AC, Tecle H, English JM, Stanton R, Wu JC.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4885-91. doi: 10.1016/j.bmcl.2010.06.073. Epub 2010 Jun 17.

PMID:
20620059
43.

Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.

DiNitto JP, Deshmukh GD, Zhang Y, Jacques SL, Coli R, Worrall JW, Diehl W, English JM, Wu JC.

J Biochem. 2010 Apr;147(4):601-9. doi: 10.1093/jb/mvq015. Epub 2010 Feb 10.

PMID:
20147452
44.

The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay.

Tecle H, Feru F, Liu H, Kuhn C, Rennie G, Morris M, Shao J, Cheng AC, Gikunju D, Miret J, Coli R, Xi SH, Clugston SL, Low S, Kazmirski S, Ding YH, Cao Q, Johnson TL, Deshmukh GD, DiNitto JP, Wu JC, English JM.

Chem Biol Drug Des. 2009 Dec;74(6):547-59. doi: 10.1111/j.1747-0285.2009.00884.x. Epub 2009 Oct 20.

PMID:
19843080
45.

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.

Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD.

Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7. doi: 10.1073/pnas.0812413106. Epub 2009 Jan 21.

46.

Design and optimization of diclofenac sodium controlled release solid dispersions by response surface methodology.

Shivakumar HN, Desai BG, Deshmukh G.

Indian J Pharm Sci. 2008 Jan;70(1):22-30. doi: 10.4103/0250-474X.40327.

47.

Human antibodies for immunotherapy development generated via a human B cell hybridoma technology.

Li J, Sai T, Berger M, Chao Q, Davidson D, Deshmukh G, Drozdowski B, Ebel W, Harley S, Henry M, Jacob S, Kline B, Lazo E, Rotella F, Routhier E, Rudolph K, Sage J, Simon P, Yao J, Zhou Y, Kavuru M, Bonfield T, Thomassen MJ, Sass PM, Nicolaides NC, Grasso L.

Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3557-62. Epub 2006 Feb 27.

49.

Minimally invasive, endoscopically assisted colostomy can be performed without general anesthesia or laparotomy.

Mattingly M, Wasvary H, Sacksner J, Deshmukh G, Kadro O.

Dis Colon Rectum. 2003 Feb;46(2):271-3.

PMID:
12576903
50.

Differing cardioprotective efficacy of the Na+/Ca2+ exchanger inhibitors SEA0400 and KB-R7943.

Magee WP, Deshmukh G, Deninno MP, Sutt JC, Chapman JG, Tracey WR.

Am J Physiol Heart Circ Physiol. 2003 Mar;284(3):H903-10. Epub 2002 Nov 21.

Supplemental Content

Loading ...
Support Center